Iovance Biotherapeutics, Inc. (IOVA) Dividend History

Iovance Biotherapeutics, Inc. (IOVA) is a biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. It specializes in T-cell therapy platforms aimed at harnessing the body's immune system to target and destroy cancer cells. The company’s primary focus is on personalized, off-the-shelf T-cell therapies for various solid tumors and hematologic malignancies.

825 Industrial Road, San Carlos, CA, 94070
Phone: (650) 260-7120
Website: https://www.iovance.com

Dividend History

Iovance Biotherapeutics, Inc. currently does not pay dividends

Company News

IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA

Iovance Biotherapeutics, Inc. (IOVA) is facing a securities class action lawsuit due to its failure to disclose material information during the class period, leading to a significant decline in its stock price.

GlobeNewswire Inc.
Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman

Iovance's cell therapy Amtagvi faced a slower-than-expected ramp-up, operational challenges, and higher-than-anticipated patient dropout rate, leading to a UBS downgrade and a securities class action lawsuit.

GlobeNewswire Inc.

Featured Companies: CODI URGN
DEADLINE ALERT for IOVA, DNUT, MSTR, DV: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has filed class action lawsuits on behalf of shareholders of Iovance Biotherapeutics, Krispy Kreme, MicroStrategy, and DoubleVerify. Investors have until the specified deadlines to file a lead plaintiff motion.

GlobeNewswire Inc.

Featured Companies: DNUT DV MSTR STRF STRK
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA

Iovance Biotherapeutics, Inc. (IOVA) is facing a class action lawsuit due to alleged failure to disclose material information during the class period, leading to a significant decline in its stock price.

GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Compass Diversified, Digimarc, Elevance Health, and Iovance and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. has filed class action lawsuits against Compass Diversified, Digimarc, Elevance Health, and Iovance Biotherapeutics, alleging various financial irregularities and misleading statements by the companies.

GlobeNewswire Inc.

Featured Companies: CODI DMRC ELV

Dividend data last updated 06/07/2025 08:50:25 UTC